Compare CFND & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFND | CGTX |
|---|---|---|
| Founded | N/A | 2007 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.5M | 158.8M |
| IPO Year | 2025 | 2021 |
| Metric | CFND | CGTX |
|---|---|---|
| Price | $5.35 | $1.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.88 |
| AVG Volume (30 Days) | N/A | ★ 951.2K |
| Earning Date | N/A | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $0.22 |
| 52 Week High | N/A | $3.83 |
| Indicator | CFND | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 55.50 |
| Support Level | N/A | $1.69 |
| Resistance Level | N/A | $1.81 |
| Average True Range (ATR) | 0.00 | 0.13 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 87.22 |
C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.